RESEARCH

Excessive interatrial adiposity is associated with left atrial remodeling, augmented contractile performance in asymptomatic population

Yau-Huei Lai1,2,3,4, Chun-Ho Yun5,6, Cheng-Huang Su1,2,3,4, Fei-Shih Yang5, Hung-I Yeh1,2,3,4, Charles Jia-Yin Hou1,2,3,4, Tung-Hsin Wu6, Ricardo C Cury8, Hiram G Bezerra9 and Chung-Lieh Hung1,2,3,4,7

1Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
2Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Hsinchu, Taiwan
3Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan
4Mackay Medical College, Taipei, Taiwan
5Department of Radiology, Mackay Memorial Hospital, Taipei, Taiwan
6Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan
7Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan
8Cardiovascular MRI and CT Program, Baptist Cardiac Vascular Institute, Miami, FL, USA
9University Hospitals Case Medical Center, Cardiovascular Department, Cleveland, OH, USA

Abstract

Purpose: Pericardial adipose tissue had been shown to exert local effects on adjacent cardiac structures. Data regarding the mechanistic link between such measures and left atrial (LA) structural/functional remodeling, a clinical hallmark of early stage heart failure (HF) and atrial fibrillation (AF) incidence, in asymptomatic population remain largely unexplored.

Methods: This retrospective analysis includes 356 subjects free from significant valvular disorders, atrial fibrillation, or clinical HF. Regional adipose tissue including pericardial and periaortic fat volumes, interatrial septal (IAS), and left atrioventricular groove (AVG) fat thickness were all measured by multidetector computed tomography (MDCT) (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). We measured LA volumes, booster performance, reservoir capacity as well as conduit function, and analyzed their association with adiposity measures.

Results: All four adiposity measures were positively associated with greater LA volumes (all \( P < 0.05 \)), while IAS and AVG fat were also related to larger LA kinetic energy and worse reservoir capacity (both \( P < 0.01 \)). In multivariate models, IAS fat thickness remained independently associated with larger LA volumes, increased LA kinetic energy and ejection force (\( j\)-coef: 0.17 & 0.15, both \( P < 0.05 \)), and impaired LA reservoir and conduit function (\( j\)-coef: −0.20 & −0.12, both \( P < 0.05 \)) after adjusting for clinical variables.

Conclusion: Accumulated visceral adiposity, especially interatrial fat depots, was associated with certain LA structural/functional remodeling characterized by impaired LA reservoir and conduit function though augmented kinetic energy and ejection performance. Our data suggested that interatrial fat burden may be associated with certain detrimental LA functions with compensatory LA adaptation in an asymptomatic population.

Key Words

- interatrial fat
- pericardial fat
- left atrial function
- MDCT
Introduction

Over the past decade, assessment of left atrial (LA) function has been shown to be crucial in maintaining adequate cardiac mechanistic performance and pump function in subjects with preserved left ventricular (LV) systolic function with sinus rhythm (1). Throughout the cardiac cycle, LA serves multiple roles. First as a reservoir receiving pulmonary venous return during ventricular systole, then as an open conduit directing the influx of blood flow into LV during early diastole, and finally as an active booster pump during late diastole (2). It is well-established that the reservoir, conduit, and booster functions of LA are key factors to ventricular filling performance, and may serve as clinical surrogate of LA dysfunction at an earlier stage (2, 3).

Several clinical risk factors, including obesity, metabolic derangements, and LV hypertrophy secondary to chronic pressure overload, had all been shown to affect LA structure and function negatively (4). Numerous studies had demonstrated that the pathogenesis between central obesity and cardiovascular diseases (5, 6) may be partially mediated by the pericardial adipose tissue, a hypothetical source of inflammatory and atherogenic cytokines with active biological effects (7, 8). As a result of its anatomic proximity and shared blood supply with the myocardium, pericardial fat had been reported to influence various aspects of cardiac function, including LA remodeling (9) and the development of atrial fibrillation (AF) (10, 11). On the other hand, far less effort had been invested in the possible effects that atrial septal fat accumulation (also known as lipomatous septal hypertrophy) may impose on specific LA mechanics.

On the basis of this hypothesis, we sought to examine the link among different sites of visceral adiposity with LA structural remodeling and its related mechanistic performances in an asymptomatic population. We also speculated that visceral fat accumulation surrounding interatrial location is associated with some components of LA functional impairment, and will further investigate these issues.

Subjects and methods

Subjects

We consecutively studied subjects who received cardiovascular health examinations from 2010 to 2013 at a tertiary medical center in Taipei, Taiwan. The clinical setting was for clinical cardiovascular risk stratification at cardiovascular outpatient service, which was similar to our previously published data (12, 13). All study subjects underwent detailed review of medical histories, along with physical examination performed in all study subjects. Clinical symptoms including angina, chest discomfort, or heart failure (e.g. exercise intolerance) were all obtained, with subspecialty transferred if appropriate. Transthoracic echocardiography, electrocardiography (ECG), and cardiac computed tomography (CT) for coronary calcium scoring were performed in all subjects. Patients with acute decompensated heart failure (HF), unstable angina, atrial flutter/fibrillation (either persistent or paroxysmal), severe valvular disease (either stenosis or regurgitation), or end-stage renal disease were excluded. A total of 356 subjects after exclusion during study period were finally enrolled. The presence of CAD was defined as a history of previous myocardial infarction, previous angioplasty, or more than 50% luminal narrowing diagnosed by coronary angiography. Hypertension was defined as systolic blood pressure above 140 mmHg, diastolic blood pressure above 90 mmHg or previously diagnosed hypertension under regular medication control. Diabetes was defined as a fasting glucose level above 126 mg/dL or previously diagnosed diabetes with medication use. Hyperlipidemia was defined as a history and/or use of lipid-lowering drugs such as statins or fibrates on a daily basis. Standardized sphygmomanometer cuff-defined resting blood pressures were measured at rest by medical staff blinded to the other test results. All baseline characteristics and information regarding anthropometric measures were collected, which included body size in terms of body mass index (BMI) and waist circumference.

This study has been approved by Mackay Memorial Hospital Institutional Review Board with adherence to research ethics (IRB number: 14MMHIS161).

Echocardiography and LA mechanics measures

Each subject underwent two-dimensional (2D) and color Doppler transthoracic echocardiography using a commercially available ultrasound system (Vivid 7, GE Medical System, Vingmed, Norway) equipped with 2–4 MHz transducer at the left decubitus position. All recorded images were measured and analyzed with clinical information blinded using a computerized off-line software (TomTec Image Arena, Munich, Germany). All measurements were averaged from three consecutive cardiac cycles. LV wall thickness and mass were determined from M-mode method. LV volumes and ejection fraction were obtained via the modified biplane Simpson method from the apical...
four- and two-chamber views according to American Society of Echocardiography recommendations (14). Diastolic functional parameters including early mitral inflow velocity (E), late mitral inflow velocity (A), deceleration time (DT), iso-volumic relaxation time (IVRT), and tissue Doppler imaging (TDI)-derived mitral annular early-diastolic velocity (e') were all obtained. The average e' velocity between LV basal septal and lateral segments was used for our statistical analysis. Average E/e' ratio was used to predict LV filling pressures (15).

For volumetric assessment of LA reservoir, conduit, and booster functions, maximum LA volume (LAV max, at end-systole, just before mitral valve opening), pre-A LA volume (LAV pre-A, immediately before atrial contraction, marked by the electrocardiographic P-wave), and minimum LA volume (LAV min, at end-diastole, when the mitral valve closes) were measured by biplane method and indexed to body-surface area (14, 16) (Fig. 1). LA reservoir function was estimated by expansion index, computed as [(LAV max–LAV min)/LAV min]×100%. LA booster function was estimated by active emptying fraction, computed as [(LAV pre-A–LAV min)/LAV pre-A]×100%. LA conduit function was estimated by passive emptying fraction, computed as [(LAV max–LAV pre-A)/LAV max]×100% (2). Advanced markers of atrial systolic function such as LA ejection force and kinetic energy were calculated according to the modified Manning method. LA kinetic energy (kdyne·cm/m²) was defined as 0.5×ρ×LA active emptying volume×A², where ρ was blood density (1.06 g/cm³) and A was late-diastolic mitral inflow velocity (cm/s) (17). LA ejection force (kdyne/m²) was defined as (0.5×ρ×LA active emptying volume×A²)/late-diastolic transmitral flow velocity time integral (VTIₚ, cm) (17). Finally, a subset sample of 50 cases was selected for comparing continuous speckle tracking analysis and manually traced method for echo-defined LA volume data in our lab, which showed high correlation (r=0.96, P<0.05). To further validate the accuracy of our echo-based LA volumes, we randomly selected 59 cases who received contrast-enhanced computed tomography (CECT) using multidetector computed tomography (MDCT) coronary artery imaging protocol during the study conduction time. LA volumes were then quantified and compared with echo-based measures which had been approved by research ethics committee.

Quantification of regional pericardial and periaortic fat

All participants had undergone MDCT originally for coronary calcium score measurement, and we reconstructed the images for visceral fat assessment. MDCT was performed by using a 16-slice scanner (Sensation 16, Siemens Medical Solutions, Forchheim, Germany) with 16 mm×0.75 mm collimation, rotation time 420 ms and tube voltage of 120 kV. In one breath-hold, images were acquired from above the level of tracheal bifurcation to below the base of heart using prospectively ECG triggering with the centre of the acquisition at 70% of the R-R interval. From the raw data, the images were reconstructed with standard kernel in 3 mm thick axial, non-overlapping slices and 25 cm field of view.

Visceral adipose tissue measurements were carried out offline (Aquarius iNtuition Cloud, TeraRecon, SanMateo, CA, USA) on a single workstation using methods described previously (18). Total pericardial adipose tissue volumes were quantified using a semi-automatic segmentation technique, in which the region of interest was defined by manually tracing the pericardial borders. Fat tissue was defined as pixels within a window of −195 to −45 HU, and pericardial fat was then selected as adipose tissue within the pericardial sac (Fig. 2A). Thoracic periaortic adipose tissue was defined as all adipose tissue surrounding the thoracic aorta extending 67.5 mm caudally from the level of the bifurcation of the pulmonary arteries (Fig. 2B). For regional fat thickness measurements, we performed multplanar reconstructions to obtain the standardized horizontal long-axis plane from axial and longitudinal two-chamber views for subsequent measurement of the interatrial septum (IAS) and left atrioventricular groove.
(AVG) based on methods validated by a previous study (19) (Fig. 2C). For reproducibility assessment, intra-observer and inter-observer coefficients of variation were determined by repeated measurement on 50 randomized cases by two experienced readers blinded to the subjects’ clinical data. The intra-observer and inter-observer coefficients of variation for pericardial fat and interatrial fat were 4.27%, 4.87% and 6.58%, 6.81%, respectively.

Statistical analysis

Continuous data were shown as mean with standard deviation. Categorical information was expressed as the frequency and proportion of prevalence, and then compared using a χ²-test or Fisher’s exact test if appropriate. Baseline continuous data were compared by a Wilcoxon nonparametric test for significant trend across regional adipose tissue (IAS) strata based on tertiles. The trend between LA/LV structural/functional parameters and increasing IAS fat volume was examined across IAS strata, with uni- and multi-variable regression models used to determine the associations between various regional adipose tissue burden and LA mechanical/functional indices (including volumes, booster performance, reservoir capacity as well as conduit function).

All data were analyzed using a commercial software STATA 8.2 package (Stata Corp, College Station, TX, USA). The significance of p level (α-value) for all analysis was two-sided, with a value less than 0.05 considered to be statistically significant.

Results

Basic information, biomarkers and adiposity measures

The associations of IAS fat with baseline demographics, biochemical, or inflammatory markers and other
Table 1  Relationship of baseline demographics, biochemical and inflammatory markers, medical histories, and other adiposity measures with interatrial fat.

<table>
<thead>
<tr>
<th>Baseline demographics</th>
<th>Interatrial fat thickness (mm)</th>
<th>1st tertile group</th>
<th>2nd tertile group</th>
<th>3rd tertile group</th>
<th>P (trend)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(n = 119)</td>
<td>(n = 119)</td>
<td>(n = 118)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td>50.25 ± 7.90</td>
<td>50.77 ± 9.05</td>
<td>54.09 ± 9.24</td>
<td>0.003</td>
</tr>
<tr>
<td>Male (%)</td>
<td></td>
<td>71 (60.17%)</td>
<td>81 (69.23%)</td>
<td>93 (78.15%)</td>
<td>0.007</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td></td>
<td>119.16 ± 16.76</td>
<td>121.34 ± 16.37</td>
<td>125.15 ± 16.63</td>
<td>0.048</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td></td>
<td>75.90 ± 10.42</td>
<td>74.91 ± 10.79</td>
<td>77.92 ± 10.47</td>
<td>0.113</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td>23.40 ± 2.77</td>
<td>24.49 ± 2.64</td>
<td>25.86 ± 3.00</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>WC (cm)</td>
<td></td>
<td>80.72 ± 8.43</td>
<td>83.42 ± 8.19</td>
<td>89.15 ± 8.06</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td></td>
<td>25.69 ± 6.70</td>
<td>25.28 ± 6.17</td>
<td>27.86 ± 7.15</td>
<td>0.051</td>
</tr>
<tr>
<td>Biochemical data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td></td>
<td>95.26 ± 11.15</td>
<td>99.81 ± 17.57</td>
<td>104.90 ± 26.21</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td>5.84 ± 0.54</td>
<td>5.93 ± 0.59</td>
<td>6.15 ± 1.05</td>
<td>0.079</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td></td>
<td>201.04 ± 36.34</td>
<td>198.30 ± 35.07</td>
<td>198.26 ± 36.87</td>
<td>0.786</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td></td>
<td>122.47 ± 56.54</td>
<td>139.09 ± 88.32</td>
<td>160.07 ± 92.94</td>
<td>0.004</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td></td>
<td>133.48 ± 31.30</td>
<td>128.48 ± 33.20</td>
<td>129.93 ± 30.09</td>
<td>0.444</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td></td>
<td>51.97 ± 12.89</td>
<td>51.96 ± 14.35</td>
<td>45.69 ± 10.61</td>
<td>0.001</td>
</tr>
<tr>
<td>eGFR (mL/min/m²)</td>
<td></td>
<td>85.76 ± 13.70</td>
<td>86.88 ± 16.07</td>
<td>83.22 ± 19.95</td>
<td>0.173</td>
</tr>
<tr>
<td>hs-CRP (mg/dL)</td>
<td></td>
<td>0.18 ± 0.16</td>
<td>0.17 ± 0.16</td>
<td>0.33 ± 0.34</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin (µIU/mL)</td>
<td></td>
<td>5.35 ± 2.87</td>
<td>5.88 ± 3.17</td>
<td>7.17 ± 3.87</td>
<td>0.004</td>
</tr>
<tr>
<td>HOMA-IR (IU/mL)</td>
<td></td>
<td>1.24 ± 0.83</td>
<td>1.44 ± 0.92</td>
<td>1.86 ± 1.33</td>
<td>0.001</td>
</tr>
<tr>
<td>CCS</td>
<td></td>
<td>145.9 ± 38.51</td>
<td>105.4 ± 21.49</td>
<td>123.52 ± 52.56</td>
<td>0.117</td>
</tr>
<tr>
<td>Medical histories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia (%)</td>
<td></td>
<td>0.09 ± 0.29</td>
<td>0.14 ± 0.35</td>
<td>0.14 ± 0.35</td>
<td>0.534</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td></td>
<td>0.22 ± 0.42</td>
<td>0.27 ± 0.45</td>
<td>0.34 ± 0.47</td>
<td>0.138</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td></td>
<td>0.08 ± 0.27</td>
<td>0.14 ± 0.35</td>
<td>0.22 ± 0.42</td>
<td>0.008</td>
</tr>
<tr>
<td>CAD history (%)</td>
<td></td>
<td>0.01 ± 0.11</td>
<td>0.05 ± 0.22</td>
<td>0.04 ± 0.19</td>
<td>0.337</td>
</tr>
<tr>
<td>Adiposity measures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pericardial fat (mL)</td>
<td></td>
<td>79.25 ± 21.96</td>
<td>83.06 ± 27.96</td>
<td>80.72 ± 29.13</td>
<td>0.539</td>
</tr>
<tr>
<td>Pericardial fat index (mL/m²)</td>
<td></td>
<td>28.46 ± 5.91</td>
<td>42.04 ± 5.73</td>
<td>57.69 ± 9.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Periaortic fat (mL)</td>
<td></td>
<td>7.64 ± 3.09</td>
<td>8.49 ± 3.91</td>
<td>8.19 ± 4.14</td>
<td>0.208</td>
</tr>
<tr>
<td>Periaortic fat index (mL/m²)</td>
<td></td>
<td>3.19 ± 1.53</td>
<td>4.02 ± 1.51</td>
<td>5.63 ± 2.07</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Left AVG fat (mm)</td>
<td></td>
<td>3.99 ± 1.02</td>
<td>5.37 ± 0.67</td>
<td>7.42 ± 1.77</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostatic model assessment-estimated insulin resistance; CCS, coronary calcium score; CAD, coronary artery disease; AVG, atrioventricular groove.

Adiposity measures were summarized in Table 1. Among all 356 participants, 245 (68.8%) were men, with an average age of 51.8±8.8 years. With increasing IAS fat measure, there were stepwise increases in BMI and waist circumference (trend P<0.001). Furthermore, increasing fat were significantly associated with graded increase in fasting glucose, triglyceride, hs-CRP, insulin and insulin resistance (HOMA-IR), as well as decreased HDL (all trend P<0.005). The mean total pericardial fat volume and volume index were 80.39±26.05 mL, 42.97±13.68 mL/m², which were within the normal limit (125 mL or 68 mL/m²) as suggested by a previous literature (20). Mean IAS thickness was 5.7±1.71 mm, which was comparable to the control group data of a previous study (20). Both pericardial and periaortic fat volumes indexed to body-surface area had significant increase along with increased IAS thickness (all P<0.001). For those subjects without any known hypertension, diabetes, hyperlipidemia or coronary artery disease, the mean IAS thickness was 5.48±1.7 mm (n=219). A search of our hospital database found that 329 (92.4% available) of the participants were followed at least once in outpatient clinics. The median follow-up period was 3.4 years. Four patients had documented atrial fibrillation (AF); two were hospitalized for heart failure. Five of those six patients were clustered in the third IAS tertile group; the remaining one came from the second tertile group (P=0.025).
Echocardiographic parameters and multivariate analysis

The relationship between IAS fat thickness and various LV structural and functional parameters is presented in Table 2. Mean LAV max index, LAV pre-A index and LAV min index were 18.34 ± 6.04 mL/m², 10.79 ± 3.75 mL/m², 7.5 ± 3.02 mL/m², respectively. We observed a high correlation between echo and CT-based LA maximum volume among 59 random cases in our lab (Echo: 40.6 ± 12.8 ml vs CT: 48.6 ± 11.5 ml, r=0.94, P<0.001), with a mean difference of 7.91 ± 4.25 mL (95% CI: −9.02 to −6.81).

Increasing IAS tertiles were associated with graded increases in LV wall thickness, chamber size as well as total LV mass and LV mass index (all trend P<0.001), whereas global LV systolic function remained relatively unaffected. There were no remarkable differences in mitral inflow Doppler-derived diastolic functional parameters across IAS tertiles, except for a trend towards higher A velocity with greater IAS (trend P: 0.018). As for TDI-derived parameters, there were significant reductions in average e’ velocity (trend P: 0.014) and increases in E/e’ ratio (trend P: 0.001).

We showed that greater IAS fat was strongly related to all three volume indices (1st vs 3rd tertiles: 16.85 vs 19.87 mL/m² for LAV max index, 9.73 vs 12.03 mL/m² for LAV pre-A index, 6.68 vs 8.61 mL/m² for LAV min index, all P<0.05) (Table 3). With each increasing IAS

| Table 2 | Relationship of LV structural/functional parameters with interatrial fat. |
|-----------------|-----------------|-----------------|-----------------|
|                | 1st tertile group | 2nd tertile group | 3rd tertile group |
| Interatrial fat thickness (mm) | (n = 119) | (n = 119) | (n = 118) |
| IVS (mm)       | 9.33 ± 1.22     | 9.60 ± 1.15     | 10.14 ± 1.15     | <0.001 |
| PWT (mm)       | 9.03 ± 1.20     | 9.50 ± 1.22     | 9.99 ± 1.10      | <0.001 |
| LVEDV (mL)     | 96.58 ± 14.87   | 102.68 ± 15.22  | 109.32 ± 16.68   | <0.001 |
| LVESV (mL)     | 30.93 ± 7.35    | 32.89 ± 6.94    | 34.87 ± 7.85     | <0.001 |
| LVM (g/m²)     | 141.90 ± 33.70  | 156.82 ± 34.22  | 175.31 ± 39.15   | <0.001 |
| LVMI (g/m²)    | 77.83 ± 15.89   | 83.23 ± 14.88   | 89.21 ± 16.60    | <0.001 |
| LVEF (%)       | 68.95 ± 2.76    | 68.56 ± 3.74    | 68.29 ± 3.46     | 0.463  |
| E (cm/s)       | 61.51 ± 14.91   | 61.57 ± 13.48   | 60.51 ± 16.76    | 0.637  |
| A (cm/s)       | 60.56 ± 12.28   | 62.59 ± 12.69   | 66.18 ± 15.82    | 0.018  |
| DT (ms)        | 204.36 ± 45.60  | 206.94 ± 51.67  | 211.69 ± 48.49   | 0.383  |
| IVRT (ms)      | 91.44 ± 15.92   | 93.34 ± 14.32   | 94.89 ± 17.36    | 0.121  |
| e’ (cm/s)      | 10.2 ± 2.66     | 8.76 ± 3.02     | 7.8 ± 2.04       | 0.014  |
| E/e’           | 7.17 ± 2.21     | 7.9 ± 4.03      | 8.49 ± 3.19      | 0.001  |

IVS, interventricular septum; PWT, posterior wall thickness; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction; E, early mitral inflow velocity; A, late mitral inflow velocity; DT, deceleration time; IVRT, isovolumetric relaxation time; e’, early-diastolic tissue velocity.

| Table 3 | Relationship of LA structural/functional parameters with interatrial fat. |
|-----------------|-----------------|-----------------|-----------------|
|                | 1st tertile group | 2nd tertile group | 3rd tertile group |
| Interatrial fat thickness (mm) | (n = 119) | (n = 119) | (n = 118) |
| LAV max index (mL/m²) | 16.85 ± 5.53 | 18.37 ± 6.03 | 19.87 ± 6.23³ | 0.001 |
| LAV pre-A index (mL/m²) | 9.73 ± 3.20 | 10.65 ± 3.55 | 12.03 ± 4.17³ | <0.001 |
| LAV min index (mL/m²) | 6.68 ± 2.55 | 7.27 ± 2.65 | 8.61 ± 3.51³ | <0.001 |
| LA reservoir function/expansion index (%) | 159.44 ± 46.64 | 157.94 ± 45.65 | 142.4 ± 40.8³ | 0.004 |
| LA booster function/active emptying fraction (%) | 31.94 ± 7.37 | 31.92 ± 6.71 | 29.72 ± 6.52² | 0.022 |
| LA conduit function/passive emptying fraction (%) | 41.84 ± 5.77 | 41.59 ± 6.03 | 39.97 ± 5.58³ | 0.009 |
| LA kinetic energy (kdynes-cm/m²) | 5.84 ± 2.56 | 7.13 ± 3.55³ | 7.75 ± 3.84³ | <0.001 |
| LA ejection force (kdynes/m²) | 1.12 ± 0.41 | 1.26 ± 0.46³ | 1.29 ± 0.43³ | 0.001 |

LAV max, LA maximum volume; LAV pre-A, LA pre-A volume; LAV min, LA minimum volume.
³P<0.05 versus 1st tertile group by ANOVA.
²P<0.05 versus 2nd tertile group by ANOVA.
tertile, there was a significant decrease in all three functional parameters (1st vs 3rd tertiles: 159.44 vs 142.4% for reservoir function/expansion index, 31.94 vs 29.72% for booster function/active emptying fraction, 41.84 vs 39.97% for conduit function/passive emptying fraction, all \( P < 0.05 \)). However, both LA kinetic energy and ejection force had graded increases (1st vs 3rd tertiles: 5.84 vs 7.75 kdynes cm\(^{-2}\) for LA kinetic energy, 11 vs 16% for LA ejection force).

Table 4: Univariate and multivariate models regarding the differential association between LA structural/functional parameters and regional fat measures (standardized \( \beta \)-coefficients shown in table).

<table>
<thead>
<tr>
<th>Model</th>
<th>Pericardial fat</th>
<th>Periaortic fat</th>
<th>Left AVG fat</th>
<th>IAS fat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>0.11*</td>
<td>0.14**</td>
<td>0.14*</td>
<td>–0.07</td>
</tr>
<tr>
<td></td>
<td>0.12*</td>
<td>0.13*</td>
<td>0.13*</td>
<td>–0.06</td>
</tr>
<tr>
<td></td>
<td>0.15**</td>
<td>0.19***</td>
<td>0.18**</td>
<td>–0.15**</td>
</tr>
<tr>
<td></td>
<td>0.22***</td>
<td>0.32***</td>
<td>0.30***</td>
<td>–0.19***</td>
</tr>
<tr>
<td>Model 2</td>
<td>0.09</td>
<td>0.12*</td>
<td>0.12*</td>
<td>–0.05</td>
</tr>
<tr>
<td></td>
<td>0.11*</td>
<td>0.11*</td>
<td>0.11*</td>
<td>–0.03</td>
</tr>
<tr>
<td></td>
<td>0.14***</td>
<td>0.16**</td>
<td>0.15**</td>
<td>–0.11*</td>
</tr>
<tr>
<td></td>
<td>0.21</td>
<td>0.29***</td>
<td>0.29***</td>
<td>–0.16**</td>
</tr>
<tr>
<td>Model 3</td>
<td>0.05</td>
<td>0.09</td>
<td>0.09</td>
<td>–0.05</td>
</tr>
<tr>
<td></td>
<td>0.09</td>
<td>0.07</td>
<td>0.08</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>0.09</td>
<td>0.10</td>
<td>0.11</td>
<td>–0.11</td>
</tr>
<tr>
<td></td>
<td>0.19**</td>
<td>0.30***</td>
<td>0.29***</td>
<td>–0.20*</td>
</tr>
</tbody>
</table>

LAV max, LA maximum volume; LAV pre-A, LA pre-A volume; LAV min, LA minimum volume; AVG, atrioventricular groove; IAS, interatrial septum.

Model 1: Univariate.
Model 2: Multivariate: adjusted for age, gender.
Model 3: Multivariate: adjusted for age, gender, eGFR, LV mass, history of hypertension, diabetes, hyperlipidemia or CAD.

\*P<0.05; \**P<0.01; \***P<0.001.
1.12 vs 1.29 kdynes/m² for LA ejection force, both
P < 0.05). Figure 3 shows the linear regression analysis
and scatter plots for the afore-mentioned parameters
in relation to IAS fat thickness. The fitted lines point
to a gradual decline in all three functional indices and
increases in both LA kinetic energy and ejection force
(all P < 0.001).

Table 4 presents both univariate and multivariate
models regarding the differential association between
LA structural/functional parameters and regional fat
measures. In univariate analysis, both IAS and left AVG
fat thickness were significantly related to increased LA
volumes, impaired LA reservoir function (β-coef: −0.15,
P < 0.01 for AVG fat; β-coef: −0.19, P < 0.001 for IAS fat),
and increased kinetic energy (β-coef: 0.17, P < 0.01 for
AVG fat; β-coef: 0.18, P < 0.001 for IAS fat). In addition,
thicker IAS fat was also associated with decreased LA
booster function (β-coef: −0.13, P < 0.05), conduit func-
tion (β-coef: −0.15, P < 0.01), and increased ejection force
(β-coef: 0.14, P < 0.001). In the multivariate analysis,
IAS fat thickness remained significantly associated with
increased LA volumes (β-coef: 0.19, 0.3, 0.29, respectively,
all P < 0.01), increased LA kinetic energy and ejection force
(β-coef: 0.17 & 0.15, respectively, both P < 0.05), impaired
LA reservoir and conduit function (β-coef: −0.2 & −0.12,
respectively, both P < 0.05) after adjusting for age, gender,
eGFR, LV mass, and history of hypertension, diabetes,
hyperlipidemia or CAD.

Discussion

In this study, we observed that regional adiposity in terms
of interatrial fat was partially associated with several LV
geometric alterations and diastolic dysfunction. Further-
more, greater IAS was associated with LA structural
and functional adaptations including LA enlargement,
attenuated reservoir, conduit and booster performance,
yet globally enhanced kinetic energy and ejection force.
After control of multiple variables, these associations
remained mostly significant except for booster function.

Potential mechanisms for the association of interatrial
fat and atrial function

Lipomatous septal hypertrophy is a well-documented
clinical condition associated with sick sinus syndrome
(21) and atrial arrhythmias (22, 23, 24). Previous studies
based on both necropsy (25) and image data (19, 26) had
confirmed that these fatty infiltrates in the interatrial
septum are proportionately correlated with total pericar-
dial fat volume and one-dimensional fat thickness over
grooved segments. In a previous study by Shin et al. [19],
after dividing 160 patients into persistent AF, paroxys-
mal AF and control groups, the authors demonstrated
that increased interatrial fat thickness was associated
with AF severity. However, to the best of our knowledge,
no investigation had yet been aimed specifically at the
mechanistic link between interatrial fat and LA structural
remodeling and functional alterations.

It has been previously reported that pericardial fat was
independently associated with metabolic derangements,
fatty liver disease, insulin resistance and systemic inflam-
mation, by utilizing CT measures (13, 27). Histological
studies of lipomatous septal hypertrophy have shown an
abundance of inflammatory cells and fibrosis permeating
throughout the fatty infiltrates (25). It has also been sug-
gested that certain cytokines and inflammation process
from accumulated adiposity may have direct adverse
effects on LA mechanics or mediated arrhythmogenesis
(19, 26, 28), leading to consequent structural remodeling,
conduction disturbances and AF incidence (29). This study
compared the associations among LA regional adiposity,
pericardial, periaortic fat, and several LA structural/ 
functional measures respectively. Since only interatrial
fat had significant correlations with LA functions after
multivariate adjustment, this may imply that interatrial fat
should be viewed as a separate entity from pericardial fat.
In contrast, AV groove fat may be regarded an extension
of pericardial fat by sharing similar characteristics. While the
enveloping pericardial fat may affect global cardiac func-
tion by both mechanical compression and cytokine secre-
tion, the different anatomic nature of interatrial septal fat
suggests a more biochemically oriented pathway.

Previous studies on patients with mild-to-moderate heart
failure symptoms have shown that higher LA contractile
or ejection force and greater kinetic energy may exist in these
patients compared with healthy people (17, 30), possibly as
compensation for maintaining resting cardiac output (31,
32). Our study showed that greater fat depots surrounding
LA, especially interatrial fat, was accompanied by decreased
reservoir function though augmented LA kinetic energy
and ejection force. This supports the concept that such
regional adipose tissues can be beneficial by preserving
myocardial energy supply under certain circumstances, yet
simultaneously impose certain negative effects generated
by inflammatory process. Similar paradoxical effects of
central obesity have been widely explored in previous
literature (33, 34, 35). Investigators had previously observed
an early reduction in LA reservoir and conduit functions...
along with compensatory increase in contractile function among patients with either hypertension (36, 37) or heart failure with preserved ejection fraction (32), possibly at the expense of LA enlargement. Another reason for LA volume expansion was believed to result from compensatory increased preload as a result of the optimal use of Frank-Starling mechanism to provoke atrial muscle shortening and contractility for same reasons (38). Taken together, our findings can be interpreted as subclinical LA functional disturbances possibly driven by the detrimental effects of interatrial fat, leading to impaired LA reservoir and conduit functions. On the meanwhile, cardiac performance was preserved by LA enlargement and augmented LA ejection force and kinetic energy in this process.

**Potential clinical implications**

A previous study showed that individuals without AF history who had increased atrial fat infiltration may be exposed to higher risk of developing AF, according to the ARIC risk score. They also found that IAS width strongly correlated with the extent of atrial fat infiltration (39). So far, impaired LA reservoir and conduit functions in individuals with central obesity or metabolic derangements had been speculated to be associated with AF substrate formation (10, 11), which may be independent of LA size (40). While different “weight” of various sites adiposity on cardiac structure/functions or electrical properties may exist (8, 9, 28), we and others demonstrated that IAS fat infiltrate may be of potential clinical significance (19, 38). In particular, as reported before, higher prevalence of atrial arrhythmias (for instance, AF) and overt LA remodeling had been observed with lipomatous septal hypertrophy (24). Compared with other fat depots, interatrial fat burden was more strongly linked to deteriorated LA mechanics of several aspects in our work after accounting for clinical covariates. An in-depth understanding of such findings may therefore help to identify a specific population at higher risk of AF development in daily practice. Thus, we speculate that early prevention of such fat infiltration or aggressive control of underlying clinical risks might prevent AF development, which may require further confirmation in future research.

**Limitations**

There are several limitations in our study. The first, our study has a male gender predominance, which may be somewhat biased. Secondly, this survey is mainly retrospective and cross-sectional, without an elaborate longitudinal follow-up of clinical outcomes. The actual number of patients who developed AF or heart failure was very low. This could be partially explained by the practice of national health insurance, which mandates nearly full population coverage in general disease management. However, the lack of ambulatory ECG monitoring rendered it impossible to determine whether silent paroxysmal arrhythmias might be missed. Thirdly, we primarily assessed LA volume by 2D echocardiography at specific time points, which is limited in accuracy due to the left atrium’s complex geometry and surrounding structures. Data of advanced imaging techniques such as speckle tracking and 3D-based echocardiography were also limited. However, we also performed CT measurements on nearly one-sixths of the study population, and the high correlation suggested that the echocardiographic method can be validated. Finally, although most data from our analysis had high statistical significance, the actual correlation was not strong, indicating that interatrial fat is only a minority in the wide range of multiple factors accounting for variations in LA mechanics.

**Conclusions**

This study showed that in an asymptomatic population, regional adipose tissue may have a negative impact on the LV geometry and LA remodeling process, which primarily manifested as LA enlargement accompanied by functional decline of several LA mechanics, including conduit and reservoir functions. These remodeling processes were associated with increased LA global kinetic energy and ejection force at the hemodynamic level, which may serve to compensate for those functional deteriorations of LA in asymptomatic population. More studies may be required to determine whether this association with LA function was mainly a causative of interatrial fat deposition, or vice versa.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This study was in part supported by funds NSC 101-2314-B-195-020, NSC 103-2314-B-010-005-MY3, NSC 103-2314-B-195-001-MY3 and funds from Medical Research Department, Mackay Memorial Hospital.
Authors' contributions
YH Lai performed the echocardiographic measurements, participated in study design, and drafted the manuscript. CH Yun performed the CT measurements. Ch Su, HI Yeh, and CJ Hou participated in study design and provided assistance in literature review. FS Yang, TS Wu, RC Cury, and HG Bezerra provided assistance in CT measurement and method standardization. CL Hung conceived this study concept, performed statistical analysis, and revised the manuscript. All authors have read and approved the final manuscript.

References

28 Tselentakis EV, Woodford E, Chandy J, Gaudette GR & Saltman AE 2006 Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. *Journal of Surgical Research* 135 68–75. (doi:10.1016/j.jss.2006.03.024)


